Finance

Genomic-marker company completes $5.4 million series A financing

Published in Women's Health Weekly, February 12th, 2004

Exagen Diagnostics, Inc., an emerging company in the discovery and development of practical prognostic genomic markers for serious diseases, announced the closing of its series A financing, which raised more than $5.4 million.

Exagen is in the process of validating a breast cancer prognostic that will help physicians determine which newly diagnosed patients should consider aggressive treatment, and is developing a hepatitis C prognostic that will identify patients who are most likely to respond to treatment with interferon and ribaviran. The funding round was led by Tullis-Dickerson & Co. with the participation of vSpring Capital and Wasatch Venture Fund.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2004-02-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry